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ABSTRACT The human T-cell leukaemia virus type 1 (HTLV-1) is associated with pulmonary
inflammation. Indigenous Australians in central Australia have a very high prevalence of HTLV-1
infection and we hypothesised that this might contribute to high rates of bronchiectasis in this population.
80 Indigenous adults with confirmed bronchiectasis, each matched by age, sex and language to two
controls without bronchiectasis, were recruited. Case notes and chest imaging were reviewed, HTLV-1
serology and the number of peripheral blood leukocytes (PBLs) infected with HTLV-1 (pro-viral load
(PVL)) were determined, and radiological abnormality scores were calculated. Participants were followed
for a mean±SD of 1.14±0.86 years and causes of death were determined.
Median (interquartile range) HTLV-1 PVL for cases was 8-fold higher than controls (cases 213.8
(19.7–3776.3) copies per 105 PBLs versus controls 26.6 (0.9–361) copies per 105 PBLs; p=0.002).
Radiological abnormality scores were higher for cases with HTLV-1 PVL ⩾1000 copies per 105 PBLs and
no cause of bronchiectasis other than HTLV-1 infection. Major predictors of bronchiectasis were prior
severe lower respiratory tract infection (adjusted OR (aOR) 17.83, 95% CI 4.51–70.49; p<0.001) and an
HTLV-1 PVL ⩾1000 copies per 105 PBLs (aOR 12.41, 95% CI 3.84–40.15; p<0.001). Bronchiectasis (aOR
4.27, 95% CI 2.04–8.94; p<0.001) and HTLV-1 PVL ⩾1000 copies per 105 PBLs (aOR 3.69, 95% CI
1.11–12.27; p=0.033) predicted death.
High HTLV-1 PVLs are associated with bronchiectasis and with more extensive radiological
abnormalities, which may result from HTLV-1-mediated airway inflammation.
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Bronchiectasis is characterised by the pathological dilatation of bronchi, which is thought to result from
cycles of infection and inflammation in individuals with a dysregulated immune response [1, 2]. Marked
differences exist between populations in their prevalence of non-cystic fibrosis (non-CF) bronchiectasis.
For example, prevalence in non-Indigenous populations of high-income countries is highest for females
and the elderly [3, 4]. Indigenous people of such countries are disproportionately affected [5], and disease
occurs at a younger age [6, 7], more often involves males [5, 8] and outcomes are worse than for their
non-Indigenous peers [5, 8]. In central Australia, for example, >1.0% of Indigenous adults were admitted
with complications of bronchiectasis over 7 years and 34% died during 7.5 years at a mean age of only
42.5 years [5].
The reason for such a high prevalence of bronchiectasis in the Indigenous population of central Australia
is unclear. Tuberculosis, measles and pertussis are important causes of bronchiectasis in low- and
middle-income countries, but are uncommon in central Australia. Other recognised causes, such as
immunoglobulin deficiency, are rare [9, 10] and CF has not been reported [9, 10]. Childhood non-CF
bronchiectasis has therefore been attributed to recurrent pneumonia resulting from overcrowded housing
and barriers to personal hygiene [10]. The adult prevalence of infection with the human T-cell leukaemia
virus type 1 (HTLV-1) exceeds 40% in some central Australian communities [11] and this may contribute
to high rates of adult non-CF bronchiectasis [5, 12].
HTLV-1 is a human retrovirus that infects at least 5–10 million people worldwide [13]. The virus is
transmitted by exposure to infected lymphocytes in breast milk and blood, and through sexual intercourse
[14]. HTLV-1-associated diseases are thought to arise in up to 10% of people with HTLV-1 [14].
Recognised complications include adult T-cell leukaemia/lymphoma (ATL), inflammatory disorders
(HTLV-1-associated myelopathy (HAM) [15], alveolitis [16] and uveitis [14]) and severe infections with
parasites, such as Strongyloides stercoralis [14]. Risk of disease increases markedly among people with
higher numbers of HTLV-1-infected cells in peripheral blood (HTLV-1 pro-viral load (PVL)) [17]. The
HTLV PVL varies as much as 1000-fold between individuals, but is relatively stable over time within an
individual [18].
Cross-sectional studies suggest that HTLV-1-associated pulmonary inflammation involves the alveoli,
bronchi and bronchioles [16, 19–23]. Case series from several countries also suggest an association with
bronchiectasis [22–24]; however, this is supported by a single small case–control study that did not control
for post-infective bronchiectasis [12]. We now report the results of a larger case–control study that




A single, 186-bed hospital, Alice Springs Hospital (ASH), serves central Australia, a region of ~1000000 km2
in which most Indigenous people live in conditions of considerable socioeconomic disadvantage. Patients
requiring bronchoscopy are flown to tertiary referral centres 1500 km away.
Recruitment and case–control matching
The study aimed to prospectively recruit all Indigenous adults (aged ⩾18 years) admitted to ASH with a
diagnosis of bronchiectasis ( June 1, 2010 to December 31, 2013). Potential cases were identified by the
project coordinator (H. Pham) from the patient management system, and these were eligible for
recruitment if 1) admitted to ASH for >48 h, and 2) the diagnosis of bronchiectasis met American College
of Chest Physicians criteria [25]. Admission for >48 h was required to ensure recruitment in primary
languages by Aboriginal research team members, unaware of HTLV-1 serostatus, who worked standard
office hours. Among 120 adults admitted with a diagnosis of bronchiectasis in the time period, 106 (94%)
were recruited. Chest high-resolution computed tomography (HRCT) for 104 potential cases was
independently reviewed by two consultant radiologists (V. Au and S. Hatami), blind to HTLV-1 status,
using the Picture Archiving and Communication System with InteleViewer software (www.intelerad.com).
26 participants were excluded because radiological criteria for bronchiectasis were not met (figure 1).
Chest HRCT was not available for two cases: bronchiectasis was confirmed by chest radiography findings
of cystic bronchiectasis (n=1) and bronchography in childhood (n=1).
Controls were Indigenous adults admitted to surgical or medical wards during the same period with 1) no
lower respiratory tract infection (LRTI), 2) no evidence of bronchiectasis on chest radiography during the
study period (no chest radiography: n=15 controls) and 3) no discharge diagnosis of bronchiectasis or
HTLV-1-associated diseases (ATL, HAM, uveitis or infective dermatitis) to end of follow-up [14]. In
central Australia, HTLV-1 seroprevalence varies with age, sex and place of origin [26]. The latter is closely
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related to primary Indigenous languages, which were used to match cases and controls due to population
mobility. Controls were matched to cases in a 2:1 ratio, by age group (age of case ±10 years), sex and
primary Indigenous language by the project coordinator (H. Pham) who was blinded to HTLV-1 status.
Reasons for admission, comorbid conditions and results of relevant investigations were extracted from case
notes for each admission (first admission to recruitment date) using a standardised data collection form.
Data are presented to date of diagnosis for cases unless otherwise stated because LRTI presentations
increase after bronchiectasis develops. Data for controls are presented to date of recruitment. Cases and
controls were followed-up by reviewing medical records. Causes of death were determined to October 31,
2016, from death certificates held at the registries of births, deaths and marriages, Northern Territory of
Australia and South Australia. Survival of participants with no death certificate was confirmed by hospital
or clinic attendance to August 12, 2018 (no recorded attendance: n=6 controls).
Blood tests
All cases and controls were tested for HTLV-1 and S. stercoralis serology. Routine investigations to
establish a cause of bronchiectasis included full blood examination, serum immunoglobulins (IgG, IgA and
IgM), IgG subclasses, total IgE, Aspergillus specific IgE and IgG, antinuclear antibodies, extractable nuclear
antibodies, rheumatoid factor, and α1-antitrypsin. Tests for CF are not routine for Indigenous adults at
ASH because no case has been found despite extensive testing [9, 10].
Radiological scoring
A “radiological abnormality score” was calculated from chest HRCT [12]. Briefly, each lobe was scored
independently for bronchiectasis severity (0–3), bronchial wall thickening (0–3), mucus plugging/
centrilobular nodules (0, 1), sacculation (0, 1), parenchymal changes of ground-glass density (0, 1) and air
trapping/emphysema (0, 1). A maximum score of 10 could therefore be assigned to each lobe. This was
also assigned to lobes with complete collapse/cicatrisation. The lingular segment of the left upper lobe was




Any diagnosis of bronchiectasis
















FIGURE 1 Recruitment flowchart for cases and matching to controls: recruitment was based on discharge
diagnosis. Among 106 subjects with a discharge diagnosis of bronchiectasis, 104 were examined by chest
high-resolution computed tomography (HRCT), which confirmed the diagnosis in 78 cases. Chest HRCT was
not available for two cases for which diagnosis was confirmed by chest radiography findings of cystic
bronchiectasis and by bronchography. Each case was then matched to two controls who were admitted during
the study period with 1) no lower respiratory tract infection on admission, 2) no evidence of chronic lung
disease on chest radiography and 3) no discharge diagnosis of either bronchiectasis or a human T-cell
leukaemia virus type 1-associated disease. Reasons for admission of controls included: 1) surgical
management n=121 (75.6%) (skin and soft tissue infections n=45, orthopaedic n=22, general surgical n=20,
trauma n=27, pancreatitis n=3, burns n=3, tonsillectomy n=1), 2) medical reasons n=36 (22.5%) (heart disease
n=11, renal disease n=8, neurological disease n=6, gastroenterological disorders n=4, diabetic ketoacidosis
n=1, constipation n=2, pelvic inflammatory disease n=1, alcohol withdrawal n=1, malnutrition n=1, acute
rheumatic fever n=1) and 3) to care for other patients n=3 (1.9%).
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Clinical definitions
LRTI required a clinical diagnosis in the case record. Pneumonia was an LRTI with consolidation on
chest imaging. Severe pneumonia required any of 1) lobar consolidation in two or more lobes, 2) lung
abscess/empyema or 3) intensive care unit admission. Severe bronchiolitis required oxygen therapy for
>48 h. Severe LRTI included severe pneumonia, severe bronchiolitis and pulmonary tuberculosis.
Chronic obstructive pulmonary disease (COPD) required a clinical diagnosis with radiological findings
of hyperinflation and reduced lung markings. Baseline spirometry was generally unavailable because of
low attendance rates for outpatient lung function tests. Post-infective bronchiectasis was diagnosed
when symptom onset clearly followed a prior severe LRTI. Chronic respiratory failure was defined as a
stable daytime arterial oxygen tension ⩽55 mmHg (⩽7.3 kPa). Allergic bronchopulmonary aspergillosis
(ABPA) was diagnosed according to AGARWAL et al. [27]. Sputum yield was defined as the number of
cultures from which a pathogen was isolated divided by the number of cultures performed at least
1 month apart. Eosinophilia was defined as an eosinophil count in peripheral blood >0.7×109 L−1 for
>12 months.
HTLV-1 studies
Peripheral blood buffy coats were prepared at ASH and stored at −80°C, batched and transferred to the
National Serology Reference Laboratory (Melbourne, Australia), where analyses were performed blinded to
the patient’s clinical state. Samples were initially screened for HTLV-1 plasma antibodies on both the
Serodia HTLV-I particle agglutination assay (Fujirebio, Tokyo, Japan) and Murex HTLV-I+II test kit
(Murex Diagnostics, Dartford, UK). Repeatedly reactive specimens underwent confirmatory testing using a
more specific supplemental test, i.e. Western blot assay (HTLV-I/II Blot2.4; MP Biomedicals Asia Pacific,
Singapore). HTLV-1c PVL was determined by real-time PCR as previously described [28]. The number of
HTLV-1 copies per peripheral blood leukocyte (PBL) was expressed as HTLV-1 copies per 105 PBLs. The
lower limit of detection was 6.5 copies for HTLV-1 (95% CI 5.4–8.4 copies) and 15.6 copies for albumin
(95% CI 12.9–20.0 copies), used as the internal control and to enumerate nucleated cells.
Ethics statement
The study was approved by the Central Australian Human Research Ethics Committee (HREC 14-202).
All participants provided written consent.
Statistical analysis
Categorical variables were summarised using frequency (percentage). Continuous variables were
summarised using mean with standard deviation or median (interquartile range (IQR)) as appropriate.
Follow-up of cases and controls was to October 31, 2016. Cases and controls were compared using a
Chi-squared, Fisher’s exact or Wilcoxon rank-sum test as appropriate. Logistic regression was used to
examine associations between bronchiectasis and demographic characteristics, clinical history and
laboratory markers for all cases and their controls and for the subgroup with HTLV-1. Predictors of death
from any cause among cases were also studied using logistic regression. The Hosmer–Lemeshow test was
used to assess each model for goodness of fit. For all analyses p<0.05 was considered significant. All
analyses were conducted using Stata version 15 (StataCorp, College Station, TX, USA).
Results
Demographic and clinical characteristics of patients are shown in table 1. Reasons for admission of
controls are listed in figure 1. Bronchiectasis was first diagnosed in childhood in 13 (16.3%) cases at a
mean±SD age of 5.3±4.1 years; 67 cases (83.7%) were diagnosed as adults (age ⩾18 years) at a mean±SD age
of 43.1±15.4 years. Males were most often affected (60%) (table 1). High rates of smoking were recorded
for both groups (table 1).
Clinical details of bronchiectasis cases
Bronchiectasis followed severe LRTI in 21 cases: pneumonia in 16 cases (n=9 adults and n=7 children),
bronchiolitis in four children and pulmonary tuberculosis in one adult. Other pathogens included
Streptococcus pneumoniae (n=3), adenovirus (n=2), methicillin-susceptible Staphylococcus aureus (n=1)
and Klebsiella pneumoniae (n=1). LRTIs were complicated by persistent lobar collapse in eight cases.
Chronic lobar collapse was also documented prior to diagnosis for five cases with no identifiable
antecedent event. 11 out of 13 (84.6%) cases diagnosed with bronchiectasis in childhood, but only nine
out of 67 (13.4%) cases diagnosed in adulthood, were preceded by a severe LRTI (table 1).
Bronchiectasis was associated with combined IgA and IgG1–3 deficiency in one HTLV-1 uninfected case.
Four cases had positive Aspergillus specific IgE with total IgE >1000 IU·mL−1, but none met other criteria
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for ABPA. Although nontuberculous mycobacteria were more often cultured from the sputum of cases,
these were not pathogens typically associated with pulmonary disease (supplementary table S1).
Cases were more likely to have HTLV-1 (42 out of 80 (52.5%) versus controls 53 out of 160 (33.1%);
p=0.004) and to have a higher HTLV-1 PVL (table 1). The median (IQR) HTLV-1 PVL for cases was
8-fold higher than that of controls: cases 213.8 (19.7–3776) copies per 105 PBLs versus controls 26.6
(0.9–361) copies per 105 PBLs (p=0.002) (table 1).
Radiological scores for bronchiectasis, bronchial wall thickening, saccular bronchiectasis, cystic
bronchiectasis and overall radiological abnormality scores were significantly higher for cases with HTLV-1
PVL ⩾1000 copies per 105 PBLs and no identifiable cause for bronchiectasis other than HTLV-1 infection
(table 2). There was no difference in HTLV-1 PVL between cases with and without an alternative cause for
bronchiectasis (figure 2).




Male 48 (60.0) 96 (60.0) 1.000
Remote residence childhood 53 (93.0) 82 (85.4) 0.237
Remote residence adulthood 48 (60.0) 99 (61.9) 0.449
Tobacco# 51 (63.8) 114 (71.3) 0.237
Alcohol¶ 54 (67.5) 103 (64.4) 0.631
Comorbidities
COPD+ 8 (10.0) 6 (3.8) 0.051
Asthma§ 1 (1.3) 0 (0.0) 0.333
Heart disease 19 (23.8) 38 (23.8) 1.000
CCF 7 (8.8) 11 (6.9) 0.603
IHD 11 (13.8) 22 (13.8) 1.000
RHD 1 (1.3) 5 (3.1) 0.380
Diabetes 23 (28.8) 67 (41.9) 0.048
Chronic kidney diseaseƒ 11 (13.8) 38 (23.8) 0.161
Chronic liver disease 9 (11.3) 5 (3.1) 0.011
HTLV-1 infection
HTLV-1 infected## 42 (52.5) 53 (33.1) 0.004
HTLV-1 PVL copies per 105 PBLs 213.8 (19.7–3776) 26.6 (0.9–361) 0.002
Admission details¶¶
Childhood admissions
Any admission++ 55 (68.8) 72 (45.0) 0.035
Any LRTI admission§§ 40 (50.0) 52 (32.5) 0.009
ICU LRTI admissions 0.04±0.19 0.01±0.11 0.317
LRTI admissions 1 (0–3) 1 (0–2) 0.041
Adulthood admissions
Any admission++ 49 (61.3) 68 (42.5) 0.005
Any LRTI admission§§ 49 (61.3) 67 (41.9) 0.005
ICU LRTI admissions 0.14±0.47 0.06±0.33 0.1166
LRTI admissions 4 (1–10) 0 (0–1) <0.001
Severe LRTIƒƒ 21 (26.3) 3 (1.9) <0.001
Mortality
Died 31 (38.8) 18 (11.3) <0.001
Age at death years 50 (36–59) 58.5 (44–63) 0.0579
Data are presented as n, n (%), median (interquartile range) or mean±SD, unless otherwise stated. COPD:
chronic obstructive pulmonary disease; CCF: congestive cardiac failure; IHD: ischaemic heart disease;
RHD: rheumatic heart disease; HTLV-1: human T-cell leukaemia virus type 1; PVL: pro-viral load; PBL:
peripheral blood leukocyte; LRTI: lower respiratory tract infection; ICU: intensive care unit. #: any history
of tobacco smoking recorded in medical records; ¶: any history of harmful alcohol use recorded in
medical records; +: history of COPD recorded in case notes with chest radiography findings consistent with
this diagnosis (prior to bronchiectasis diagnosis for cases); §: clinical diagnosis of asthma recorded in
case notes with an increased forced expiratory volume in 1 s >12% and >200 mL after administration of
bronchodilators; ƒ: stage ⩾2; ##: HTLV-1 Western blot or HTLV-1c PCR positive; ¶¶: prior to diagnosis for
cases and to time of recruitment for controls; ++: admission for any reason; §§: admission for LRTI;
ƒƒ: LRTI due to severe pneumonia, severe bronchiolitis or tuberculosis at any age (see Methods).
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Predictors of bronchiectasis
The major predictors of bronchiectasis in a multivariable model were any admission with a severe LRTI
(adjusted OR (aOR) 17.83, 95% CI 4.51–70.49; p<0.001) and an HTLV-1 PVL ⩾1000 copies per 105 PBLs
(aOR 12.41, 95% CI 3.84–40.15; p<0.001) (table 3).
Among participants with HTLV-1, every 100 unit increase in HTLV-1 copies per 105 PBLs was, on
average, associated with 1.07 times the risk of bronchiectasis, which was 5.68-fold higher among

































FIGURE 2 Dot plots with median (interquartile range (IQR)) comparing human T-cell leukaemia virus type 1
(HTLV-1) pro-viral load (PVL) for controls (n=53), cases with HTLV-1 and risk factors for bronchiectasis (n=10),
and cases with no risk factors predisposing to bronchiectasis other than HTLV-1 infection (n=32). Risk factors
for bronchiectasis included severe pneumonia (n=5), empyema (n=2), pulmonary abscess (n=1), pulmonary
tuberculosis (n=1) and severe childhood bronchiolitis (n=1). Median (IQR) HTLV-1 PVLs for controls, cases with
other risk factors and cases without risk factors were 3.28 (0.49–5.89), 6.01 (2.98–7.58) and 5.35 (3.01–8.32)
log unit copies per 105 peripheral blood leukocytes (PBLs), respectively. HTLV-1 PVLs were significantly
higher for cases with (p=0.0178) and without (p=0.0108) risk factors for bronchiectasis when compared with
controls (Mann–Whitney test). There was no difference in HTLV-1 PVLs between groups for cases.
TABLE 2 Radiological abnormality scores for cases without alternative causes of
bronchiectasis according to human T-cell leukaemia virus type 1 (HTLV-1) pro-viral load (PVL)
Low PVL (<1000 copies per
105 PBLs)




Bronchiectasis score 4.53±3.67 7.25±3.86 0.039
Bronchial wall thickening 3.74±3.14 6.17±3.01 0.038
Cystic bronchiectasis 0.68±1.25 1.67±1.37 0.028
Saccular bronchiectasis 0.50±0.99 1.47±1.55 0.025







Data are presented as n or mean±SD, unless otherwise stated. PBL: peripheral blood leukocyte. Combined
radiological scores for all lobes for cases with HTLV-1 for which no alternative cause of bronchiectasis
was found. Each lobe was scored separately by radiologists blinded to HTLV-1 status (see Methods). The
lingular segment of the left upper lobe was regarded as a separate lobe. One case (HTLV-1 PVL 242
copies per 105 PBLs) for which high-resolution computed tomography was not available for review was not
included in this analysis. 10 cases with alternative causes were excluded (severe pneumonia n=5;
empyema n=2; pulmonary abscess n=1; pulmonary tuberculosis n=1; severe childhood bronchiolitis n=1).
#: rank-sum test; ¶: a composite score comprising those for all other radiological parameters
(bronchiectasis, bronchial wall thickening, cystic bronchiectasis, saccular bronchiectasis, mucus plugging/
centrilobular nodules and ground-glass opacities).
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factors significantly associated with bronchiectasis in a multivariable model included a prior severe LRTI, a
non-severe childhood LRTI and strongyloidiasis (table 4).
Mortality
During 272.9 years of follow-up after recruitment, 31 cases (38.8%) and 18 controls (11.3%) died at a
median age of 50 and 58.5 years, respectively. Most cases died due to complications of bronchiectasis (28
out of 31 (90.3%)); the major cause of death for controls was cardiovascular disease (seven out of 18
(38.9%)). The proportions of subjects who died among those without HTLV-1, those with an HTLV-1
TABLE 3 Predictors of bronchiectasis among 80 cases and their 160 controls
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Age# 1.01 (0.99–1.03) 0.355
Remote residence in adulthood¶ 1.25 (0.59–2.65) 0.556
Admitted in childhood 1.88 (1.06–3.32) 0.031
Any LRTI+
Childhood 2.08 (1.20–3.60) 0.009 1.90 (0.93–3.86) 0.078
Adulthood 2.19 (1.27–3.80) 0.005
Number of LRTIs§
Childhood 1.15 (0.95–1.40) 0.151
Adulthood 1.24 (1.14–1.36) <0.001
Number of ICU LRTIsƒ 1.28 (0.56–2.95) 0.558
Severe LRTI## 18.63 (5.36–64.77) <0.001 17.83 (4.51–70.49) <0.001
HTLV-1 infected¶¶ 2.23 (1.29–3.86) 0.004
HTLV-1 PVL (categorical)++
Uninfected Reference Reference
Low HTLV-1 PVL 1.50 (0.81–2.76) 0.194 1.92 (0.88–4.19) 0.101
High HTLV-1 PVL 7.98 (2.93–21.72) <0.001 12.41 (3.84–40.15) <0.001
Sputum cultures
Yield§§ 2.23 (1.29–3.87) 0.004 1.46 (0.65–3.29) 0.359
Haemophilus influenzae 1.47 (1.18–1.83) 0.001 2.07 (1.35–3.16) 0.001
Streptococcus pneumoniae 1.56 (1.09–2.24) 0.014 0.47 (0.21–1.04) 0.064
Pseudomonas aeruginosa 2.79 (0.76–10.32) 0.124
NTMƒƒ 12.89 (1.52–109.01) 0.019 44.78 (2.10–952.84) 0.015
Eosinophilia### 2.88 (1.65–5.03) <0.001
Strongyloides¶¶¶ 2.23 (1.29–3.89) 0.004 1.81 (0.80–4.09) 0.153
Cellulitis/skin abscess 0.81 (0.68–0.99) 0.028 0.60 (0.45–0.80) 0.001
Infective dermatitis+++ 2.70 (1.28–5.70) 0.009
Scabies§§§ 6.06 (1.93–19.02) 0.002
Tobaccoƒƒƒ 0.71 (0.40–1.25) 0.238
Alcohol#### 1.15 (0.65–2.03) 0.631
LRTI: lower respiratory tract infection; ICU: intensive care unit; HTLV-1: human T-cell leukaemia virus type 1;
PVL: pro-viral load; NTM: nontuberculous mycobacteria. #: risk of bronchiectasis per 5 years. ¶: residence
>80 km from Alice Springs documented in medical records. +: admitted with any non-severe LRTI prior to
diagnosis (cases) or date of recruitment (controls). §: number of admissions with LRTIs prior to diagnosis
(cases) or date of recruitment (controls). ƒ: number of ICU admissions for LRTI in childhood and adulthood
combined prior to diagnosis for cases or to date of recruitment for controls. ##: severe
pneumonia (n=16), severe bronchiolitis (n=4) and pulmonary tuberculosis (n=1) at any age (see Methods);
includes one case with combined IgA and IgG deficiency; three controls had severe LRTI (pulmonary
tuberculosis n=1, pulmonary abscess n=1, severe pneumonia n=1). ¶¶: HTLV-1 Western blot or HTLV-1c
PCR positive. ++: low HTLV-1 PVL, <1000 copies per 105 peripheral blood leukocytes (PBLs); high HTLV-1
PVL, ⩾1000 copies per 105 PBLs. §§: the number of pathogens isolated divided by the number of sputum
samples collected, calculated once for each admission. ƒƒ: NTM isolated from six cases prior to diagnosis
included 1) a novel species that could not be identified together with a scotochromogenic mycobacterium,
2) Mycobacterium avium complex in a patient with pulmonary tuberculosis and 3) Mycobacterium simiae
(isolated once from one case and twice from another); mycobacteria were not identified to species level in
two cases and one control from which an NTM was isolated only once. ###: eosinophilia recorded on at
least two occasions 12 months apart (prior to diagnosis for cases). ¶¶¶: Strongyloides seropositive or larvae
identified in stool at any time prior to date of recruitment. +++: infective dermatitis recorded in case notes
(cases HTLV-1+ n=10, HTLV-1− n=2; controls HTLV-1+ n=1, HTLV-1− n=5). §§§: clinical diagnosis of scabies
recorded in case notes (no case diagnosed by microscopy). ƒƒƒ: any history of tobacco smoking recorded in
case notes. ####: any history of harmful alcohol consumption recorded in case notes.
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PVL <1000 copies per 105 PBLs and those with HTLV-1 PVL ⩾1000 copies per 105 PBLs were 28 out of
145 (19.3%), 11 out of 72 (15.2%) and 10 out of 23 (43.5%), respectively (p=0.031).
Univariable predictors of death included increasing age, bronchiectasis, COPD, HTLV-1 PVL ⩾1000
copies per 105 PBLs, congestive cardiac failure and complications of bronchiectasis. In an adjusted model,
bronchiectasis, COPD and HTLV-1 PVL ⩾1000 copies per 105 PBLs remained predictive of death (table 5).
Discussion
Indigenous Australians have among the highest prevalence rates of adult non-CF bronchiectasis and the
worst outcomes reported [5]. In the present study, the mean age of diagnosis was only 43 years and nearly
40% of cases died during the study period at a median age of 50 years. This reflects the 100-fold higher
prevalence of bronchiectasis among Indigenous adults relative to their non-Indigenous peers in central
Australia [5] and the gap in life expectancy of 20 years between Indigenous and non-Indigenous adults
TABLE 4 Predictors of bronchiectasis among 95 human T-cell leukaemia virus type 1
(HTLV-1)-infected subjects
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Age# 1.01 (0.88–1.16) 0.870
Remote residence¶ 1.14 (1.01–1.28) 0.034 2.30 (0.92–6.52) 0.115
Admitted in childhood 1.78 (0.76–4.17) 0.183
Any LRTI admission+
Childhood 2.79 (1.18–6.58) 0.019 2.11 (1.11–4.02) 0.023
Adulthood 3.02 (1.28–7.14) 0.012
Respiratory admissions§
Childhood 1.49 (1.03–2.16) 0.032
Adulthood 1.41 (1.17–1.71) <0.001
Severe LRTIƒ 3.92 (0.97–15.85) 0.055 5.45 (1.78–16.71) 0.003
HTLV-1 PVL## 1.07 (1.02–1.12) 0.006
HTLV-1 PVL (categorical)¶¶
Low HTLV-1 PVL Reference Reference
High HTLV-1 PVL 5.33 (1.86–15.22) 0.002 5.68 (1.81–17.89) 0.003
Sputum cultures
Yield++ 4.24 (1.55–11.60) 0.005
Haemophilus influenzae 1.67 (1.16–2.42) 0.006
Streptococcus pneumoniae 3.56 (1.36–9.29) 0.010
Pseudomonas aeruginosa 1.27 (0.08–20.89) 0.686
NTM§§ 2.60 (0.23–29.70) 0.442
Eosinophiliaƒƒ 2.54 (1.09–5.91) 0.030
Strongyloides### 2.53 (1.40–4.58) 0.002 2.44 (1.22–4.89) 0.012
Infective dermatitis¶¶¶ 3.76 (1.15–12.34) 0.029
Scabies+++ 7.23 (1.49–35.09) 0.014
Tobacco§§§ 0.94 (0.40–2.24) 0.897
Alcoholƒƒƒ 1.79 (0.72–4.42) 0.208
LRTI: lower respiratory tract infection; PVL: pro-viral load; NTM: nontuberculous mycobacteria. #: risk of
bronchiectasis per 5 years. ¶: residence >80 km from Alice Springs in adulthood. +: admitted with any non-
severe LRTI prior to diagnosis (cases) or date of recruitment (controls). §: number of LRTI admissions
prior to diagnosis (cases) or date of recruitment (controls). ƒ: severe pneumonia (n=8),
severe bronchiolitis (n=1), and pulmonary tuberculosis (n=1) at any age (see Methods); three controls with
HTLV-1 had a severe LRTI (pulmonary tuberculosis n=1, pulmonary abscess n=1, severe pneumonia n=1).
##: odds of bronchiectasis per 100 unit increase in HTLV-1 copies per 105 peripheral blood leukocytes
(PBLs). ¶¶: low HTLV-1 PVL, <1000 copies per 105 PBLs; high HTLV-1 PVL, ⩾1000 copies per 105 PBLs.
++: the number of pathogens isolated divided by the number of sputum samples collected, calculated once
for each admission. §§: NTM isolated from four cases prior to diagnosis included 1) Mycobacterium avium
complex in a patient with pulmonary TB and 2) Mycobacterium simiae (isolated twice); NTM were not
identified to species level in two cases from which an NTM was isolated only once. ƒƒ: peripheral blood
eosinophilia recorded on at least two occasions 12 months apart (prior to diagnosis for
cases). ###: Strongyloides seropositive or larvae identified in stool at any time prior to date of recruitment
(cases n=18 (Strongyloides seropositive n=18, larvae in stool n=0); controls n=6 (Strongyloides seropositive
n=5, larvae in stool n=1)). ¶¶¶: infective dermatitis recorded in case notes (cases HTLV-1+ n=10, HTLV-1−
n=2; controls HTLV-1+ n=1, HTLV-1− n=5). +++: clinical diagnosis of scabies recorded in case notes (no case
diagnosed by microscopy). §§§: any history of tobacco smoking recorded in case notes. ƒƒƒ: any history of
harmful alcohol consumption recorded in case notes.
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with this condition [8]. Our finding that prior admissions with severe LRTI and high HTLV-1 PVL
predicted bronchiectasis may contribute to this disparity; HTLV-1 infection is rare in non-Indigenous
Australians [29]. A high HTLV-1 PVL was also associated with more extensive radiological abnormalities
among cases for which HTLV-1 was the only identifiable cause of bronchiectasis and was an independent
predictor of death during follow-up. These observations have not been reported previously.
Bronchiectasis is the end result of a “vicious cycle” of inflammation and infection caused by heterogeneous
conditions that dysregulate the inflammatory response of susceptible individuals [1, 2]. Vaccination against
childhood respiratory infections, improved treatment of childhood bacterial infections and control of
tuberculosis has led to significant changes in the epidemiology of bronchiectasis in high-income countries
[1, 2]. However, LRTI continues to be the most frequently cited of the identifiable aetiological factors in
diverse countries, including Turkey [30, 31], the UK [32, 33] and China [34]. Similarly, post-infective
bronchiectasis due to severe LRTI was the major identified cause of bronchiectasis in our socially
disadvantaged study population, increasing risk 18-fold in an adjusted model. Nevertheless, an antecedent
severe LRTI could be identified in only nine out of 67 cases diagnosed in adulthood.
HTLV-1 is recognised to have a tropism for the pulmonary parenchyma [16]. Pulmonary involvement is
associated with infiltration of HTLV-1-infected lymphocytes [35, 36] and an inflammatory cytokine milieu
in bronchoalveolar lavage fluid [37]. In large Japanese case series, chest HRCT was abnormal in 30–61%
of adults with HTLV-1, including bronchiectasis in 15.6–22.5% of cases and bronchitis/bronchiolitis in
TABLE 5 Predictors of any death among cases and their controls
Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Male 1.61 (0.82–3.15) 0.169
HTLV-1 infected# 1.00 (0.52–1.90) 1.000
HTLV-1 infection (categorical)¶
Uninfected Reference Reference
Low HTLV-1 PVL 0.75 (0.35–1.62) 0.467 2.27 (0.93–5.54) 0.071
High HTLV-1 PVL 3.21 (1.28–8.08) 0.013 3.69 (1.11–12.27) 0.033
Age+ 1.20 (1.07–1.35) 0.002 1.15 (1.00–1.32) 0.051
Remote residence§ 0.68 (0.30–1.55) 0.354
Bronchiectasis 4.73 (2.43–9.23) <0.001 4.27 (2.04–8.94) <0.001
COPDƒ 6.20 (2.04–18.85) 0.001 3.97 (1.06–14.87) 0.040
CCF 2.81 (1.03–7.69) 0.044 2.27 (0.73–7.03) 0.155
IHD 1.93 (0.85–4.40) 0.116
RHD 0.80 (0.09–6.97) 0.837
Diabetes 0.89 (0.46–1.73) 0.739
Haemodialysis## 0.85 (0.23–3.08) 0.802
Chronic liver disease 1.10 (0.29–4.10) 0.891
Malignancy 2.74 (0.44–16.87) 0.277
Alcohol¶¶ 0.96 (0.49–1.85) 0.892
Tobacco++ 1.13 (0.57–2.26) 0.728
Eosinophilia§§ 2.17 (1.15–4.13) 0.018
Strongyloidesƒƒ 1.36 (0.68–2.72) 0.380
Bronchiectasis complications
Respiratory failure 12.01 (4.55–31.71) <0.001
Right heart failure 5.73 (1.24–26.52) 0.026
Haemoptysis 4.27 (1.03–17.75) 0.046
HTLV-1: human T-cell leukaemia virus type 1; PVL: pro-viral load; COPD: chronic obstructive pulmonary
disease; CCF: congestive cardiac failure; IHD: ischaemic heart disease; RHD: rheumatic heart disease.
31 cases and 18 controls died during follow-up. 28 cases, but no controls, died as a result of respiratory
disease. Major causes of death among controls were cardiovascular disease (n=7), malignancy (n=3) and
nonrespiratory sepsis (n=3). #: HTLV-1 Western blot or HTLV-1c PCR positive; ¶: stratified by HTLV-1 PVL
(low HTLV-1 PVL, <1000 copies per 105 peripheral blood leukocytes (PBLs); high HTLV-1 PVL, ⩾1000
copies per 105 PBLs); +: risk per 5 years; §: documented residence >80 km from Alice Springs in
adulthood; ƒ: diagnosis recorded in case notes with chest radiography findings consistent with
diagnosis (cases diagnosed before bronchiectasis, controls to date of recruitment); ##: six cases (HTLV-1+
n=3) and 12 controls (HTLV-1+ n=5) were receiving haemodialysis at time of recruitment; ¶¶: any history of
harmful alcohol consumption recorded in case notes; ++: any history of tobacco smoking recorded in case
notes; §§: peripheral blood eosinophilia recorded on at least two occasions 12 months apart (prior to
diagnosis for cases); ƒƒ: Strongyloides seropositive or larvae identified in stool at any time prior to date of
recruitment.
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23.6–29.5% of cases [22, 23]. Both conditions are more common in Indigenous Australians with HTLV-1 [28].
The pathological correlate of these clinical observations is lymphocyte infiltration into bronchiole walls [22].
Functional alterations following HTLV-1 infection of CCR4+CD4+ T-cells lead to interferon-γ production
and a putative pro-inflammatory feedback loop in HAM [38]. Infiltration of HTLV-1-infected
lymphocytes into the airways may similarly result in persistent inflammation and irreversible bronchial
wall injury.
Inflammatory diseases resulting from HTLV-1 infection are associated with higher HTLV-1 PVL [17].
Median HTLV-1 PVLs for adults with HAM are 7–16-fold greater than those of asymptomatic adults [15, 39],
and risk increases markedly when HTLV-1 PVL exceeds 1000 copies per 105 peripheral blood
mononuclear cells [15]. In the present study, the median HTLV-1 PVL was 8-fold higher for cases, and an
HTLV-1 PVL ⩾1000 copies per 105 PBLs was associated with higher bronchiectasis scores and more
extensive radiological abnormalities on chest HRCT among cases for which HTLV-1-associated pulmonary
disease was the only identifiable cause of bronchiectasis. An association between high HTLV-1 PVL and
radiological abnormalities was previously reported in a study that combined chest HRCT data for subjects
with bronchiectasis and chronic bronchitis [12]. Although HTLV-1 PVLs prior to presentation with
bronchiectasis are unknown in the present study, our findings are consistent with an HTLV-1-mediated
inflammatory process driven by high HTLV-1 PVL. High rates of bronchiectasis among otherwise
asymptomatic Japanese adults with HTLV-1 [22, 23], and associations between HAM and bronchiectasis
in the UK [40] and Brazil [24], suggest that this effect is not restricted to Indigenous Australians.
Strengths of the present study include the recruitment of nearly all eligible patients, the blinding to
HTLV-1 status of researchers who recruited subjects and radiologists who independently reviewed
imaging, and the blinding of laboratory staff to the clinical status of subjects. Moreover, all residents with a
significant LRTI are admitted to ASH, which is the only hospital serving central Australia. Sputum
mycobacterial cultures and standard blood tests for conditions associated with bronchiectasis were
performed for nearly all cases (75 out of 80 (93.8%)). Nevertheless, limitations to the study design must be
recognised. First, controls were not screened by chest HRCT. Individuals with early bronchiectasis may
therefore have been included and our results may not be applicable to less severe bronchiectasis managed
in the community. Second, all information was collected retrospectively and the diagnosis of some clinical
diagnoses, such as scabies, could not be confirmed. The interpretation of LRTI data for cases prior to
diagnosis with bronchiectasis is also limited because lengthy delays in diagnosis are common [41] and
hospital referral with less severe LRTI may be more likely for individuals with frequent LRTI
presentations.
In conclusion, two major risk factors for non-CF bronchiectasis were identified for Indigenous adults in
central Australia. A severe LRTI, frequently complicated by persistent lobar collapse, was the major
antecedent condition. Pulmonary outcomes for such patients could be improved by routine respiratory
physician follow-up. High HTLV-1 PVL was also associated with bronchiectasis and more extensive
radiological abnormalities, including higher bronchiectasis scores, among cases for which HTLV-1 was the
only identifiable cause of bronchiectasis. Notwithstanding high rates of HTLV-1 infection in central
Australia [11], there is currently no coordinated public health strategy to reduce HTLV-1 transmission
among Indigenous Australians.
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